Recent studies suggested that selective estrogen receptor downregulators (SERDs), molecules that eliminate ER expression, may have utility for treating breast cancers that have progressed on AE and/or AIs (McDonnell et al., 2015). This evidence concerns the gene ESR1 and breast cancer.